Petrosky Emiko, Bocchini Joseph A, Hariri Susan, Chesson Harrell, Curtis C Robinette, Saraiya Mona, Unger Elizabeth R, Markowitz Lauri E
MMWR Morb Mortal Wkly Rep. 2015 Mar 27;64(11):300-4.
During its February 2015 meeting, the Advisory Committee on Immunization Practices (ACIP) recommended 9-valent human papillomavirus (HPV) vaccine (9vHPV) (Gardasil 9, Merck and Co., Inc.) as one of three HPV vaccines that can be used for routine vaccination. HPV vaccine is recommended for routine vaccination at age 11 or 12 years. ACIP also recommends vaccination for females aged 13 through 26 years and males aged 13 through 21 years not vaccinated previously. Vaccination is also recommended through age 26 years for men who have sex with men and for immunocompromised persons (including those with HIV infection) if not vaccinated previously. 9vHPV is a noninfectious, virus-like particle (VLP) vaccine. Similar to quadrivalent HPV vaccine (4vHPV), 9vHPV contains HPV 6, 11, 16, and 18 VLPs. In addition, 9vHPV contains HPV 31, 33, 45, 52, and 58 VLPs. 9vHPV was approved by the Food and Drug Administration (FDA) on December 10, 2014, for use in females aged 9 through 26 years and males aged 9 through 15 years. For these recommendations, ACIP reviewed additional data on 9vHPV in males aged 16 through 26 years. 9vHPV and 4vHPV are licensed for use in females and males. Bivalent HPV vaccine (2vHPV), which contains HPV 16, 18 VLPs, is licensed for use in females. This report summarizes evidence considered by ACIP in recommending 9vHPV as one of three HPV vaccines that can be used for vaccination and provides recommendations for vaccine use.
在2015年2月的会议上，免疫实践咨询委员会（ACIP）推荐9价人乳头瘤病毒（HPV）疫苗（9vHPV，佳达修9，默克公司）作为可用于常规接种的三种HPV疫苗之一。HPV疫苗推荐在11或12岁时进行常规接种。ACIP还建议对13至26岁未接种过疫苗的女性和13至21岁未接种过疫苗的男性进行接种。对于男男性行为者以及免疫功能低下者（包括感染HIV者），如果之前未接种过疫苗，也建议在26岁之前接种。9vHPV是一种非感染性的病毒样颗粒（VLP）疫苗。与四价HPV疫苗（4vHPV）类似，9vHPV含有HPV 6、11、16和18型VLP。此外，9vHPV还含有HPV 31、33、45、52和58型VLP。9vHPV于2014年12月10日获得美国食品药品监督管理局（FDA）批准，用于9至26岁的女性和9至15岁的男性。针对这些建议，ACIP审查了16至26岁男性中9vHPV的更多数据。9vHPV和4vHPV被批准用于女性和男性。二价HPV疫苗（2vHPV）含有HPV 16、18型VLP，被批准用于女性。本报告总结了ACIP在推荐9vHPV作为可用于接种的三种HPV疫苗之一时所考虑的证据，并提供了疫苗使用建议。
